A novel extracellular role for tissue transglutaminase in matrix-bound VEGF-mediated angiogenesis by Wang, Z. et al.
OPEN
A novel extracellular role for tissue transglutaminase
in matrix-bound VEGF-mediated angiogenesis
Z Wang1,5, M Perez1,5, S Caja2, G Melino3, TS Johnson4, K Lindfors2 and M Griffin*,1
The importance of tissue transglutaminase (TG2) in angiogenesis is unclear and contradictory. Here we show that inhibition of
extracellular TG2 protein crosslinking or downregulation of TG2 expression leads to inhibition of angiogenesis in cell culture, the
aorta ring assay and in vivo models. In a human umbilical vein endothelial cell (HUVEC) co-culture model, inhibition of
extracellular TG2 activity can halt the progression of angiogenesis, even when introduced after tubule formation has commenced
and after addition of excess vascular endothelial growth factor (VEGF). In both cases, this leads to a significant reduction in
tubule branching. Knockdown of TG2 by short hairpin (shRNA) results in inhibition of HUVEC migration and tubule formation,
which can be restored by add back of wt TG2, but not by the transamidation-defective but GTP-binding mutant W241A. TG2
inhibition results in inhibition of fibronectin deposition in HUVEC monocultures with a parallel reduction in matrix-bound VEGFA,
leading to a reduction in phosphorylated VEGF receptor 2 (VEGFR2) at Tyr1214 and its downstream effectors Akt and ERK1/2, and
importantly its association with b1 integrin. We propose a mechanism for the involvement of matrix-bound VEGFA in
angiogenesis that is dependent on extracellular TG2-related activity.
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Blood vessel formation, also known as angiogenesis, is well-
regulated by a complex growth factor network, including
vascular endothelial growth factor (VEGF),1 fibroblast growth
factor1 and platelet-derived growth factor.2 Physiological
angiogenesis is essential to bring oxygen and nutrition to
the organs during development, while pathological angiogen-
esis takes place in different organs and tissues, including eye
(cornea and retina), muscle and joints and so on, among
which tumour angiogenesis is probably the most widely
reported. Strategies to inhibit the progression of pathological
angiogenesis have therefore mainly been targeted towards
these different key growth factors and their receptors or their
downstream signalling molecules. Examples include anti-
VEGF therapy using small inhibitors or monoclonal anti-
bodies.3 Unfortunately, this approach has only shown limited
success in tumour angiogenesis and vascular mimicry, with
non-specificity and toxicity arising from the anti-VEGF
treatments.4–6 As such, there is an urgency to identify other
biomarkers and major factors involved in regulating angio-
genesis, so that alternative therapeutic antagonists and
inhibitors with more specificity and less side effects can be
developed.
There have been a number of reports to suggest the
importance of the multifunctional Ca2þ -dependent protein-
crosslinking enzyme tissue transglutaminase (TG2) in the
angiogenic process.7 In the extracellular environment, TG2
can mediate both the deposition of the extracellular matrix
(ECM) components, such as fibronectin (FN), and also act as
a cell adhesion protein via its binding to cell surface
syndecan-4 and b integrins.7,8 However, even though
research has been directed to studying the role of TG2 in
angiogenesis, the actual mechanism of how this multifunc-
tional enzyme functions in the angiogenic process is still not
fully understood. Moreover, reports from different groups are
in contradiction with one another as to the mechanism of
action of TG2 and whether the enzyme is inhibitory or
stimulatory. A recent study from Jones et al.9 demonstrated
a role for TG2 in vascular mimicry, a special type of
vasculogenesis undertaken by carcinoma cells with endothe-
lial like cell properties,10 which can be independent of VEGF
and often associated with highly aggressive tumours.6 In this
work, using the bladder carcinoma ECV304, it was shown that
the activity of TG2 was essential for the tubular formation by a
process involving matrix deposition, actin cytoskeleton
organisation and focal adhesion (FA) formation, which in turn
regulate cell migration.9
Here we further study the role of TG2 in angiogenesis using
a series of different models and show that the inhibition of TG2
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activity by site-directed irreversible inhibitors or by down-
regulation of its expression by short hairpin (shRNA) prevents
the development of angiogenesis in cell culture, the aorta ring
assay and in vivo models. We describe how TG2 function is
important in angiogenesis and propose that VEGF receptor 2
(VEGFR2) signalling mediated by matrix-bound VEGFA
is dependent on a mechanism involving extracellular
TG2-related activity.
Results
Inhibition of extracellular TG2 crosslinking activity
blocks tubule formation in vitro and ex vivo models.
Site-directed irreversible TG2 inhibitors, including R294,
R283 and Z-DON, were used to block TG2 activity in both
cell and tissue models of angiogenesis. R283 and Z-DON are
cell-permeable, whereas R294 is impermeable to cells and
acts extracellularly. R294 has greater specificity (IC50, 5 mM)
for TG2 than for Factor XIIIa (IC504200mM).11,12 R283 has
equal potency for both enzymes.13,14 The commercial TG2
inhibitor Z-DON inhibits TG2 with high specificity, while
displaying less effect on the TG1 and TG3 isoforms.15 None
of the inhibitors showed any toxicity toward human umbilical
vein endothelial cells (HUVECs) or fibroblasts upto 750mM
during a 72-h culture period (Supplementary Figures 1a and 2).
R294 was first applied to HUVECs seeded in Matrigel
(Figure 1a), resulting in a reduced capacity of the HUVECs to
align and form cord-like structures. A similar reduction in
HUVEC tubule formation by R294 was also found in the
HUVECs embedded in 3D collagen gels (Figure 1b). The
effect of the TG2 inhibitor R294 on the aorta ring ex vivomodel
of angiogenesis was also undertaken. Explants were placed
into either Matrigel or a collagen thin layer gel and outgrowth
of vessel-like structures was monitored. TG2 inhibition by
R294 led to inhibition of the tubule outgrowth from the
embedded aorta in both the Matrigel and collagen (Figures
1c and d, and Supplementary Figure S3). In contrast in the
DMSO vehicle control groups, outgrowth of well-formed
endothelial tubule structures took place, which was confirmed
by using fluorescence staining for the endothelial marker
CD31, in the tubule structures (Supplementary Figure S4).
To extend our discovery for the involvement of TG2 during
tubule formation, a co-culture model was used whereby
HUVECs are seeded with human fibroblasts, resulting in
HUVEC tubule formation over 14 days.16 As shown in
Figure 2a, the addition of TG2 inhibitors led to a significant
inhibition of tubule growth over a 14-day period
(Supplementary Table S1). The ability of compounds to affect
tubule formation, including the cell-impermeable inhibitor
R294, suggests a prominent role for the TG2 at the cell
surface or in the ECM.
Previous data using the HUVEC co-culture assay indicated
the majority of in situ TG2 activity was associated with fibrous
structures around the endothelial cell tubules.14 Analysing the
presence of the enzyme via western blotting revealed that
TG2 is majorly present in the HUVECs, but not detectable in
human fibroblasts (Figure 2b). Moreover, in a co-culture
containing TG2-/-MEF cells with HUVECs, tubule like
structures were still able to form (Figure 2c). TG2 and
CD31 were found co-localised in the tubule like structures
(Supplementary Figure S5), confirming that TG2 is predomi-
nantly in the endothelial cells and indicating that tubule
formation is dependent on the TG2 present in the HUVECs.
To confirm the extracellular importance and specificity of
TG2 in the formation of HUVEC tubules, co-cultures were
incubated with the TG2-specific transamidating inactivating
monoclonal antibody D11D12. Incubation with this antibody
led to a significant reduction of tubule formation (around 50%)
(Figure 2d, Supplementary Table S1) and a significant
reduction in extracellular TG2 activity (Figure 2e). The other
monoclonal antibodies Cub7402 and TG100 (which bind to
TG2, but do not adversely affect transamination activity
(Figure 2e)) had no significant effect on tubule growth
(Figure 2d). The antibodies were shown to have no adverse
effect on HUVEC growth (Supplementary Figure S1B).
Inhibition of extracellular TG2 activity affects endothelial
cell migration. As the migration of endothelial cells is
important for tubule formation, the migratory response of
endothelial cells to TG2 inhibitors and TG2-targeted anti-
bodies was determined. A scratch-wound assay was
performed on HUVEC monolayers cultured on FN pre-
coated surfaces. Both R294- and R283-treated cells were
unable to close the wound in a time frame comparable to that
of untreated cells or cells that only received the inhibitor
vehicle (Figures 3a and b, Supplementary Movies 1–4). Wound
assays with added TG2-specific antibodies – Cub7402 and
TG100 (which do not inhibit transamidation activity) – led to
non-significant changes in the cells ability to close the
wound. In contrast with the transamidation-inactivating
antibody D11D12, wound closure was significantly slower
(Figures 3c and d).
Inhibition of TG2 can slow down growth of newly
established tubules. To examine whether the inhibition of
extracellular TG2 has a reversible or irreversible effect on
tubule formation, staged addition of inhibitor to the co-culture
was undertaken. Exposure to R294 during the first 6 days
resulted in cells acquiring a similar morphology to the non-
inhibited co-cultures when the inhibitor was removed and
cells cultured for a further 6 days without inhibitor. However,
there was a significantly lower amount (B33%) of tubular
junctions (Figure 3e and Supplementary Table S2). The
withdrawal of R294 at day 6 resulted in a partial recovery of
the total anastomosis reached at day 12, when compared
with the untreated cells, with tubule formation being
significantly lower than that observed in untreated co-
cultures (B25%). When addition of R294 was limited to the
late stage of the co-culture (from day 6 to 12), a reduction
(B20%) in the total area of tubules and a reduction (B30%)
in tubule junctions was found. Both staged treatments led to
a significant reduction in the number of tubule junctions,
suggesting that the inhibitor may be destabilising endothelial
cell outgrowth at the junction points (Figure 3e and
Supplementary Table S2).
Decreased tubule formation and migration after TG2
knockdown in HUVECs. TG2 was downregulated using
viral transduction with shRNA (knockdown; kd), resulting in a
58.5±0.5% decrease in the HUVEC TG2 protein (Figure 4a)
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and a comparable reduction in transamidation activity, when
compared with control cells containing scrambled shRNA
(scrmb) (Supplementary Figure S6a). Restoring the expres-
sion of the active enzyme (ab) and the W241A mutant
(W241) into the TG2 kd cells using lentiviral particles resulted
in the high expression of the target protein (Figure 4b).
In both Matrigel cord formation and the EC-fibroblast
co-cultures, the TG2kd cells demonstrated reduced
tubule formation (Figures 4c and d, Supplementary
Table S3). This reduced angiogenesis caused by reduced
expression of TG2 could not be reversed by addition of
exogenous active recombinant human (rh) TG2, but was
nearly restored when HUVEC-TG2kd cells were virally
transduced with the active form of the isoenzyme (ab)
(Figures 4c and d). The W241A mutant protein, which does
not have protein-crosslinking activity but intact GTP-binding
function, failed to compensate the kd of the active enzyme,
suggesting that the transamidating activity of TG2, but
not the GTP-binding activity, is essential during tubule
formation.
Figure 1 Effect of TG2 inhibitor R294 on endothelial tubule formation. (a) Inhibition of endothelial cord formation on Matrigel by R294. Representative image from three
separate experiments. HUVECs seeded at a concentration of 15 000 cells per well in 12-well plates containing Matrigel and induced to form tubule like structures in EGM
complemented medium in the presence of 100 mMR294 or vehicle control (0.01% DMSO) for 6 h. Cells were labelled with 2 mMCalcein AM for 15min and were photographed
using 484 nm excitation and 520 nm emission filter on a fluorescent microscope. (b) Inhibitory effect of R294 on HUVEC in collagen 3D culture. HUVECs (1 105/well, in 48-
well plates) were mixed with rat tail collagen solution (final concentration 1.5 mg/ml) with 50 mMTG2 inhibitor R294 or the vehicle control (0.01% DMSO) and allowed to gelify at
37 1C for 30min. Endothelial culture medium in the presence or absence of 100mM R294 or vehicle was added to the well. Following a 4-day culture period, representative
images with and without R294 are shown using a bright-field microscope (n¼ 3). (c and d) Endothelial vessel outgrowth from rat aorta ring in Matrigel or thin layer collagen.
Rat aorta rings (n¼ 4) were embedded in Matrigel (c) or a thin layer of rat tail collagen (d) and incubated with endothelial cell medium for 7 days in the presence of 100mM
R294 or vehicle (0.01% DMSO) as described in the Materials and Methods. The representative images were taken using a bright-field microscope
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Figure 2 Effect of TG2 inhibition on endothelial tubule formation in fibroblasts and EC co-cultures. (a) After incubating the V2a AngioKit co-culture for 24 h, V2a Growth
medium was introduced (day 1) in the absence or presence of either the irreversible inhibitors Z-DON, R294 or R283 at the concentrations shown, and replaced in fresh
medium every other day for 12 days. Controls contained either complete growth media alone (untreated), or the respective inhibitor vehicle (DMSO, 0.01%). Suramin or VEGF
was used for the negative and positive control, respectively. Cells were fixed in ethanol at day 12 and stained for CD31 antigen using an anti-mouse IgG secondary AP-
conjugated antibody and visualised as described in the Materials and Methods. The tubule like structures were analysed by the TCS Cellworks AngioSys Image Analysis
Software (ZHA-1800) (Supplementary Table S1), as described in the Materials and Methods. (b) The presence of TG2 in human fibroblasts and HUVECs. Western blotting
was performed to detect the presence of TG2 in fibroblasts and HUVECs, separately. a-Tubulin was used as the equal loading control. (c) Co-culture of HUVEC and
TG2 / MEF. HUVECs were induced to undergo microtubule formation in the presence of TG2 / fibroblasts using the growth media from the angiogenesis V2a Kit.
Shown is the appearance of endothelial cell microtubules at day 14 revealed by immunostaining for CD31 antigen using anti-mouse IgG secondary alkaline phosphatase
(AP)-conjugated antibody and visualised as described in the Materials and Methods.(d) Effect of different TG2-specific antibodies on endothelial cell tubule formation in the
co-culture assay. Culture medium was supplemented with either the mouse monoclonal TG2 activity neutralising antibody (D11D12, 0.1 mg/ml), the commercial anti-TG2
antibodies Cub7402 (0.5mg/ml) or TG100 (0.5mg/ml) added to the co-culture system from day 1 (24 h after seeding). Controls consisted of either untreated cultures or isotype-
matched IgG. After 12 days, the tubule formation was analysed as described in (a) (see Supplementary Table S1). (e) The effect of the antibodies D11D12, Cub7402 and
TG100 on the extracellular crosslinking activity of TG2 in the co-culture angiogenesis assay. Cells at day 9 were incubated with various concentrations of the antibodies or
isotype-matched control for 1 h at 37 1C in a 96-well microplate. Following this pre-incubation period, biotinylated cadaverine incorporation was measured as described in the
Materials and Methods. Data show mean value±S.D. after background correction (n¼ 3) for assays that contained 10mM EDTA
TG2 in angiogenesis
Z Wang et al
4
Cell Death and Disease
Reducing TG2 expression in HUVECs also resulted in the
reducedmobility of cells on FN (Figure 4e and Supplementary
Figure S7), but had no effect on cell proliferation
(Supplementary Figure S6b), confirming the importance of
TG2 in HUVEC migration. Interestingly, the reduced mobility
of HUVEC-TG2kd was not improved by the exogenous
addition of either the inactive or the active TG2 isoenzyme.
Moreover, the active enzyme becomes inhibitory at higher
concentration (1 mg/ml), which agrees with previously
published results for its effect on tubule formation.14
The inhibition of TG2 activity results in a disrupted
HUVEC morphology and FN deposition. The cell mobility
is regulated by the formation of an intracellular actin
cytoskeleton and FA formation.17 Figure 5a shows that
R294 treatment disrupted the actin cytoskeleton and FAs in
the HUVECs. This result was further confirmed in the TG2 kd
cells (Figure 5b), in which low expression of intracellular TG2
resulted in a reduced spreading ability of cells on FN with
small disorganised actin fibres present in 83±4% of the
shRNA-GFP containing cells. As FA is required during ECM
FN fibril deposition, to confirm the importance of HUVEC
TG2 in FN deposition, isolated HUVEC cells were cultured
for 48 h in the presence and absence of TG2 inhibitor R294.
Measurement of the whole population of FN deposited by
immunofluorescence showed the deposition of dense FN
fibrils in R294-treated cells was greatly reduced (Figure 5c).
This was confirmed by the inhibition of the deposition of
exogenous biotin-labelled FN by R294 (Figures 5d and 6a).
Inhibition of TG2 activity leads to a reduction in matrix-
bound VEGF and inhibition of its downstream signalling
pathway. Matrix-bound VEGF is reported to be more
important than localised VEGF secretion for induction of
endothelial cell angiogenesis and this process is highly
sensitive to the abundance of deposited FN.18 In parallel
experiments, measurement of matrix-bound VEGF by
western blotting showed it to be greatly reduced by TG2
inhibition in cell free matrix extracts, accompanied by a
reduction ECM FN (Figure 6a).
Once deposited into the ECM, VEGF can trigger the
activation of VEGFR2. Western blotting using a specific
antibody to phosphorylated-Tyr1214 VEGFR2 in HUVECs
indicated that a significant reduction in the phosphorylation
at this site was found in R294-treated HUVECs, compared
with the vehicle control samples (Figure 6b). In addition, the
reduced levels of matrix-bound VEGF and phosphorylated-
Tyr1214 VEGFR2 in the TG2 inhibited cells correlated with
significantly reduced levels of phosphorylated Akt and ERK1/2,
the downstream effector molecules of matrix-bound VEGF
signalling (Figure 6b). Interestingly, R294 also reduced the
direct interaction between VEGFR2 and b1 integrin in the
HUVEC cultures (Figure 6c), further confirming the involve-
ment of TG2 in VEGFR2-related signalling.
Our hypothesis for the relationship between TG2 andVEGF
was further tested in the co-culture model where increased
VEGF is added to the medium. The combination of increased
VEGF with R294 resulted in less tubules of longer length and
with less junctions with respect to the tubules formed with
VEGF alone. When quantified, there is a significant (B30%)
less junctions and a significant (B30%) reduction in tubules
formed in co-cultures receiving R294, compared with
increased VEGF-treated co-cultures alone (Figure 6d and
Supplementary Table S1).
Inhibition of TG2 in two separate in vivomodels leads to
reduced angiogenesis. The chick allantoic membrane
(CAM) model of angiogenesis was used as the first in vivo
model to study the involvement of TG2 in angiogenesis.
Incubation of the TG2 inhibitor R294 on the vascular area
around the chick embryo at 100mM led to a significant
reduction in angiogenesis compared with the adjacent areas
treated with the DMSO vehicle control (Figure 7a). In the
second model, Matrigel containing 10 mg/kg of erythropoietin
(EPO) to induce angiogenesis as well as inhibitors for TG2
(at 250 mM or 500mM) or their respective vehicle controls
(PBS or DMSO) were injected subcutaneously into the rear
quarter of mice. After 8 days, the Matrigel was excised and
analysed for vasculogenesis following staining with von
Willebrand factor for vessel formation and quantified using
ImageJ software (Bethesda, MD, USA). Both R292 (Figures 7b
and c) and R294 (Figures 7d and e), which show increased
specificity for TG2 over Factor XIIIa and which act extra-
cellularly, significantly inhibited blood vessel formation in the
Matrigel plug. No significant difference between the DMSO and
the PBS control treatments was found.
Discussion
TG2 is reported to have both pro- and anti-angiogenic effects.
Haroon et al.19 using a window flap model showed that
addition of exogenous TG2 inhibited tumour growth by a
mechanism involving collagen deposition and inhibition of
tumour angiogenesis. Jones et al.14 also demonstrated that
increased TG2 led to inhibition of angiogenesis in vitro and
in vivo and inhibition of tumour progression by crosslinking the
surrounding ECM.14 More recently, Martucciello et al.20
showed that the anti-angiogenic effects of TG2-targeted
coeliac antibodies were due to the stimulation of TG2 activity.
Reports also suggest that TG2 is downregulated in
endothelial cells undergoing capillary morphogenesis,21 while
Greenberg and colleagues19 demonstrated that TG2 was
pro-angiogenic after finding that its addition to a window flap
model of dermal wounding promoted angiogenesis. The
pro-angiogenic effect of TG2 has also been shown through
its binding to endostatin in a cation-dependent manner,
which under hypoxic conditions leads to stimulation of
angiogenesis.22
In this study using HUVECs plated onto Matrigel and
submerged in collagen, we first demonstrate that growth of the
tubule like structures is reduced by the cell impermeable
irreversible TG2 inhibitor R294,12 which preferentially targets
TG2 over Factor XIIIa,11 the other TG that might be present in
culture serum. Importantly, we also show that this TG2
inhibitor blocks tubule formation in aorta rings embedded
either in either Matrigel or collagen. To explore TG2
involvement in angiogenesis further, we next used the well-
established co-culture model whereby dermal human fibro-
blast are cultured over 12–14 days with HUVEC cells resulting
in highly branched tubule formation.16We show that a number
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of TG2 inhibitors block tubule formation and that the specific
TG2-transamidating activity-inactivating antibody D11D12 is
also inhibitory, confirming that the major role of TG2 is
extracellular. Using HUVECs, we also demonstrate that one
of TG2s extracellular roles in angiogenesis is in endothelial
cell migration as this could be reduced when HUVEC cells
were allowed to migrate on FN in the presence of either small
molecule TG2 inhibitors or the inactivating TG2 antibody. This
result was further confirmed using TG2 shRNA where only
reconstitution into the cells of the wt TG2, but not inactive
TG2, restored the migratory ability of cells.
One of the most important tasks in blocking angiogenesis is
halting the growth of existing blood vessels and prohibiting
new blood vessels from occurring. We demonstrate that TG2
inhibition slows down tubule formation even after 6 days of
culture with a significant reduction in both the total area of
tubules formed and of particular note the number of junctions
established, resulting in longer tubules without junctions.
Confirmation that TG2 is the target enzyme was shown
using knockdown of TG2 expression in HUVECs by shRNA. In
both the co-culture and Matrigel models, HUVECs lost their
ability to form tubule/cord-like structures. Loss of TG2 could
not be compensated by add back of the active exogenous
enzyme into the culture system, suggesting a regulated export
of TG2 to the cell surface and binding to its cell surface-
binding partners, such as syndecan-4 and FN, in order for it to
function appropriately.8,23,24 In support of this adding back of
TG2 by viral transduction, unlike the exogenous addition of
TG2, restored the ability of HUVECs transduced with TG2
shRNA to form tubules. Downregulation of TG2 could not be
compensated in a comparable manner with the mutant
(W241A) form of the enzyme, which has impaired transami-
dating activity but GTP-binding activity, indicating that TG2
protein-crosslinking activity, but not GTP-binding activity, is
required in endothelial tubule formation. The effect of TG2
shRNA on angiogenesis raised the question why TG2
knockout animals show no large phenotype changes com-
pared with the wild-type (wt) animals.25 A series of articles
from different groups demonstrated that a compensatory
mechanism is taking place in TG2 knockout mice. In a recent
study it was shown that there is a tissue-specific mechanism
taking place by other TGs to compensate the loss of the
TG2.26 Moreover, it has been reported that in TG2 knockout
macrophages, increased expression of b3 integrins was
found.27 These observations may therefore provide a valid
explanation for the phenotype found in TG2 knockout animals.
We next turned our attention to the extracellular cross-
linking roles of TG2 that might account for our observations. In
T24/38 (ECV304) cells, we demonstrated that TG2 inhibitors
blocked both cell migration and FN deposition, both of which
were key to formation of tubular structures.9 The importance
of TG2 crosslinking in FN deposition has been reported,7,8
whereas the major role for TG2 in cell adhesion is generally
related to its non-transamidating roles via binding to cell
surface syndecan-424 and b1 and 3 integrins.28 The cross-
linking activity of TG2 is essential in ECM deposition and
stabilisation, both of which are necessary for cell migration.
However, FN deposition in endothelial cells is also reported to
be important for the binding and amplification of the activity of
the angiogenic growth factor VEGF.29 VEGFR2 activation can
be mediated by VEGF when in association with matrix
proteins, and importantly this activation is likely be relevant
to the establishment of the tip cell phenotype during the
formation of a vascular sprout.30 We show that inhibition of
TG2 transamidation activity led to reduced levels of FN
deposition in HUVECs and in parallel with this, a reduced level
of matrix-bound VEGF was detectable in these cells, when
TG2 was inhibited with R294. This may account for the
observed inhibition of tubule junctions and tubule formation by
R294 even in the presence of excess VEGF. It has been
reported that once deposited into the ECM, VEGF binds to its
receptor VEGFR2, which can trigger the phosphorylation of
VEGFR2 at Tyr1214 the activation of Akt and the activation of
ERK1/2, important downstream signalling events, which
require association of VEGFR2 with b1 integrin.30 Here we
show that the reduction of ECM-bound VEGF by the TG2
inhibition reduces the phosphorylation of VEGFR2 at Tyr1214,
the phosphorylation of Akt and the activation of ERK1/2.
Importantly, TG2 inhibition also reduces the association of
VEGFR2 with b1 integrin. One of the major effects of this
signalling transduction and association of VEGFR2 with b1
integrin is to regulate cell migration by stimulating FA
formation,30,31 thus explaining our observation of reduced
migration, reduced actin cytoskeleton formation and FA
assembly in TG2 inhibited or TG2 downregulated HUVECs.
To extend our observations for the importance of TG2 in
angiogenesis, we studied the effects of TG2 inhibition in two
in vivo models – one observing vessel growth in the CAM
assay and the other using the degree of vascular growth into a
subcutaneously implanted Matrigel plug. TG2 inhibition using
cell impermeable inhibitors led to a significant reduction in
vascular growth in these two in vivo models. To sum up, our
data indicate that endothelial TG2 may be a key factor in the
angiogenic process. Importantly, its function is dependent on
protein crosslinking directed to the extracellular space. This
crosslinking function of TG2 is in part exerted through its effect
Figure 3 Migration of HUVECs on fibronectin in the presence of either TG2-specific inhibitors or specific antibodies. (a) HUVECs were seeded onto graduated 96-well
plates pre-coated with fibronectin (5 mg/ml) and allowed to reach 90–95% confluence in the presence of EGM media. Following the different treatments, as indicated in the
figure, cells were stimulated to migrate in the absence or presence of the TG2 inhibitor R294 (100mM) and R283 (100mM), with a net scratch using a multi-well wound healing
devise to prevent direct damage to the coated surface. Cell migration was continuously monitored over a period of 18 h in the ESSEN IncuCyte instrument as shown in the
graph below. The masked images are representative of the cell migration towards the wounded area at different time intervals, as indicated. (c) The same experiment as in (a)
except the inactivating antibody (D11D12, 0.1mg/ml) or the commercial anti-TG2 antibody Cub7402 or TG100 (0.5mg/ml) or their isotype controls was added to the culture
medium. (b and d) Cell migration was continuously monitored over a period of 18 h in the ESSEN IncuCyte instrument and the cell migration was quantified as the density of
the wounded area over the time, using the ESSEN IncuCyte software. (e) Staged effect of TG2 inhibition on tubule formation in the co-culture assay. HUVEC co-cultures
cultured for 12 days after adding of V2a Growth medium and treated with inhibitor vehicle (0.01% DMSO) used as the control (upper panels) or TG2 inhibitor R294. Treatments
consisted of the addition of the R294 (50 mM) from day 1 to 12, added with fresh medium every other day, or addition of the inhibitor only during the first stage of the co-culture
(from day 1 to 6), or only during the late stage (from day 6 to 12). Tubule formation was visualised and analysed as described in Figure 3 (Supplementary Table S1)
TG2 in angiogenesis
Z Wang et al
7
Cell Death and Disease
on ECM/FN deposition, which in turn facilitates the deposition
of matrix-bound VEGF and activation of VEGFR2 signalling.
Inhibition of TG2 activity therefore ultimately leads to a
reduction in VEGFR2 signalling leading to the inhibition of
angiogenesis. Importantly, these inhibitor studies undertaken
both in vitro and in vivo suggest that inhibition of TG2 could be
a potential therapeutic target in the treatment of angiogenic
pathologies.
Materials and Methods
Reagents and antibodies. The general reagents were purchased from
Sigma-Aldrich (Dorset, UK), unless stated below. Recombinant human TG2
(rhTG2), Z-DON-Val-Pro-Leu-OMe (Z-DON) and biotinylated cadaverine (BTC)
were from Zedira (Carmstadt, Germany). The monoclonal TG2 activity neutralising
antibody D11D12 (patent filing GB1209096.5, May 2012) was a kind gift of Dr. Tim
Johnson (Sheffield University, UK). The mouse IgM anti-fibroblast surface protein
antibody 1B1032 was a kind gift of Dr. Lindsay Marshall (Aston University, UK).
The TG2 inhibitors 1, 3-dimethyl-2-imidazolium derivative R283 (Freund et al.13)
Figure 4 Manipulating TG2 expression in HUVECs affects tubule formation and cell migration. (a) Western blot analysis of TG2 expression levels in lysates of HUVEC-
TG2wt and HUVEC-TG2kd (HUVECs transduced with TG2 scrambled or targeted shRNA) and (b) TG2 add back, either the active wt enzyme or the W241A mutant in the kd
HUVECs. a-Tubulin was used as a loading control and ratio of band intensity for TG2 is shown below taken from three separate experiments. (c and d) Tubule formation of
HUVECs expressing wt TG2, TG2kd or the TG2 mutants after reintroduction into the TG2kd cells. HUVEC-TG2wt, -TG2kd, -TG2ab, -TG2kd/W241A or TG2kd in the presence
of exogenously added rhTG2 (0.25mg/ml), induced to form tubule structures on Matrigel in complete EGM-2 medium as described in the Materials and Methods, for 6 h at
37 1C in 5% CO2. Cells (GFP, green) were photographed using an epifluorescent microscope as described in the Materials and Methods. (d) HUVECs as described in (c)
(GFP, green), co-cultured with human dermal fibroblast as feeder cells in the enriched EGM medium for 12 days as described in the Materials and Methods. Images were
taken as in (c). The tubule like structures shown were analysed by the TCS Cellworks AngioSys Image Analysis Software (ZHA-1800) (Supplementary Table S3), as described
in the Materials and Methods using a bright-field microscope. (e) Scratch assay for migration of HUVEC-TG2wts and HUVEC-TG2kd on FN, in the absence or presence of
exogenously added rhTG2 at different concentrations, analysed as in Figure 3
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and the peptidic TG2 inhibitors R294 and R292 were synthesised at Aston
University.12 The antibodies used in this work were listed in Supplementary Table S4.
Cell lines. HUVECs (Promocell, Heidelberg, Germany) were cultured in
endothelial growth medium (EGM) containing endothelial cell basal medium, 2%
FBS, hydrocortisone, bFGF, VEGF, hEGF, ascorbic acid, R3-IGF, heparin and
GA-100 (Lonza, Verviers, Belgium). Human dermal foreskin fibroblasts were
cultured in DMEM with 10% FBS. HEK/293TN cells (ATCC) were cultured in
DMEM/F12 with 10% Fetalclone II and 2mM L-glutamine. Co-cultures of virally
infected HUVECs and human fibroblasts were cultured according to Bishop et al.16
to optimise tubule growth. TG2 / mouse embryonic fibroblasts (MEFs) were
a kind gift of Dr. Gerry Melino (University of Rome, Tor Vergata, Italy) and cultured
in DMEM containing 10% FBS, 1% non-essential amino acids and 2mM
L-glutamine.
Figure 5 The effect of TG2 inhibition of HUVECmorphology and FN deposition. (a) Representative images (n¼ 3) from monolayer HUVECs treated with 100mM R294 or
vehicle for 48 h and the actin cytoskeleton (green) and FAs (vinculin, red, as pointed out by the arrow heads) staining was performed and visualised as described in the
Materials and Methods. Nuclear counterstaining of cells used 4, 6-diamidino-2-phenylindole (DAPI; blue). (b) Cytoskeletal organisation of HUVEC-TG2wt and HUVEC-TG2kd.
Morphological comparison of the spreading ability of HUVEC-TG2wt and HUVEC-TG2kd, when assessed for actin stress fibre formation. HUVECs expressing the viral
constructs (GFP, green colour) were plated on FN-coated cover slips in the presence of EGM complemented medium. TRITC-labelled phalloidin (red) was used to stain actin
fibres and then examined by confocal microscopy as described in the Materials and Methods. (c) The effect of TG2 on ECM FN deposition by HUVECs. Representative image
from HUVECs treated with 100mM TG2 inhibitor R294 or vehicle for 48 h before immunostaining for extracellular FN as described in the Materials and Methods. Cells were
counter stained with DAPI. The ECM FN was visualised using fluorescence microscopy as described in the Materials and Methods. (d) The inhibition of biotin-labelled FN
deposition by R294 in HUVECs. Biotin-labelled FN 50 nM was added into HUVEC mono-cell layer as described in the Materials and Methods with 100mM R294 or with the
vehicle control. After a 48-h incubation period, the presence of biotin-labelled FN was detected using Cy5-conjugated Strep-Avidin and the fluorescence signal was visualised
via confocal microscopy. Bar, 25 mm
TG2 in angiogenesis
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Lentiviral constructs. The GFP-tagged lentiviral vectors including TG2
shRNA, scrambled shRNA, wt TG2, the W241A mutant TG2 were previously
described.33 For the ‘add-back’ experiments, the conserve mutation of wt TG2 and
the W241A mutant TG2 constructs were generated by using the Stratagene
QuickChange II XL, to avoid the effect of the shRNA.
Forward: 50-GAT CCA GGG TGA CAA GAG TGA AAT GAT TTG GAA CTT CCA
CTG CTG GGT GG-30
Reverse: 50-CCA CCC AGC AGT GGA AGT TCC AAA TCA TTT CAC TCT TGT
CAC CCT GGA TC-30
Production of lentiviral particles and infection of HUVECs. HEK-
293TN were grown to 50% confluency in DMEM/F12 with 10% Fetalclone II in
150mm culture dishes. Cells were transfected with the following viral vectors using
Lipofectamine2000 (Invitrogen, Life Technologies, Paisley, UK). Before transfection,
the medium was changed to DMEM/F12 with 2% Fetalclone II. The ratio of pPAX,
VSV-G and target vector for the transfection was 9mg : 4.5mg : 6mg. The cells were
then placed in a 33 1C incubator and after a 48-h incubation, the medium containing
the viral particles was filtered through a 0.2-mM PES syringe filter and aliquoted. The
aliquots were snap-frozen in liquid nitrogen and kept at 80 1C until use.
HUVECs were transduced with the viral particles for 5–6 days to allow for
expression of the constructs. The media was half-replaced with fresh media every 3
days. Expression of the constructs was confirmed by fluorescence microscopy or
western blotting.
Angiogenesis assay using a V2a Angiokit angiogenesis
co-culture system. The V2a AngioKit assay a pre-frozen form of the
AngioKit assay (TCS Cellworks, Buckingham, UK) was used to study tubule
formation in co-cultures of HUVECs and primary human fibroblasts.16 Following
Figure 6 The effect of TG2 inhibition on VEGF deposition and signalling. (a) Reduction of matrix VEGF and FN by inhibition of TG2. HUVECs mono-cell culture treated
with 100mM R294 or 0.01% DMSO vehicle control for 48 h. The ECM fractions from HUVECs culture were collected and western blotted for VEGF, using a specific anti-VEGF
antibody as described in the Materials and Methods. The deposition of biotin-labelled FN in the ECM after western blotting was detected by using HRP-conjugated Extr-Avidin
and the ratio of the bands taken from three separate experiments is as shown.(b) The phosphorylation of VEGFR2, ERK1/2 and Akt in HUVECs is regulated by TG2. HUVECs
mono-cell culture treated with R294 or DMSO vehicle were isolated after 48 h growth and the cell lysates used in western blotting to detect the phosphorylated VEGFR2 at
Tyr1214, ERK1/2 (p-ERK1/2) and Akt (p-Akt). Total VEGFR2, ERK1/2 and Akt was used as the loading control as described in the Materials and Methods. The ratio of the
bands taken from three separate experiments is as shown. (c) The inhibitory effect of R294 on the direct interaction between VEGFR2 and b1 integrin via co-
immunoprecipitation. Anti-b1 integrin antibody was used to pull down the b1 integrin immuno-complex in the HUVECs with or without R294 treatment for 48 h, the presence of
VEGFR2 was detected via western blotting by using anti-VEGFR2 antibody, while the rabbit IgG was used as the negative control. The ratio of the bands taken from three
separate experiments. (d) Effect of R294 on VEGF-stimulated angiogenesis. Co-cultures were grown for 12 days either untreated, or in the presence of VEGF (2 ng/ml) or
R294 (100mM), or VEGF (2 ng/ml) plus R294 (100mM). Shown is the appearance of endothelial cell tubes at day 12 revealed by the immunostaining for CD31, which was
analysed by image analysis as in Figure 2 (Supplementary Table S1)
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seeding, medium was replaced at day 2 by fresh growth medium and changed
every 2 days over 9–14 days. At day 2, treatments were introduced to the cells as
further described in the figures and figure legends. To visualise the tubule
structures, cells were fixed in cold ethanol (70%) at room temperature for 30min
and stained with the anti-human CD31 primary antibody for 1 h at 37 1C and
detected using the goat anti-mouse IgG alkaline phosphatise (ALP)-conjugate
secondary antibody. Suramin, an inhibitor of angiogenesis, was used as the
negative control. Increased addition of VEGF was used as the positive control as
supplied by the manufacture. Tubules were quantified by ELISA using ALP soluble
substrate p-nitrophenol phosphate. Tubules were finally stained using BCIP/NBT
substrate for 15–20min at 37 1C. The images were photographed with a  4
objective using bright-field microscopy (Nikon, Surrey, UK) and tubule formation
quantified using the TCS Cellworks AngioSys Image Analysis Software (ZHA-1800).
Addition of suramin, an inhibitor of angiogenesis, and extra VEGF both supplied by
the manufacturer were used as the negative and positive controls, respectively.
Matrigel endothelial cord formation assay. Phenol red-free basement
membrane Matrigel (BD, Oxford, UK) with reduced grown factors was defrosted at
4 1C and used to coat 12-well plates, 100ml/well. Plates were incubated at 37 1C
for 30min to allow the basement membrane to form a thin layer of gel. HUVECs,
wt or cells transduced with lentiviral particles (1.5 105 in complete EGM
medium), were plated in the matrigel-coated well and incubated with or without
Figure 7 (a) Effect of TG2 inhibitor R294 on angiogenesis using the in vivo CAM assay. Chick embryo after 6 days of growth in the presence of R294 at100 mM or vehicle
(0.01% DMSO) applied on disks in the same egg, as described in the Material and Methods. The accompanying histogram represents quantification of the vascular branches
in presence or absence of the inhibitor R294. Bars represent the mean number of vascular branches in arbitrary units (AU)±S.D. (n¼ 5 per group). Quantification was
assisted by computer assisted analysis using ImageJ. *Po0.05.indicates difference from vehicle control (b–e). The effect of TG2 inhibition on in vivo angiogenesis in a mice
Matrigel plug model. (b and d) Show the immunostaining of blood vessels using Von Willebrand as the angiogenesis marker in the presence of TG2 inhibitors R292 (b) and
R294 (d) at the concentrations of 250 mM and 500mM. The area of the blood vessels was quantified using Image J software and expressed as mean value±S.D. (n¼ 5).
(c and e) PBS and DMSO (0.01%) were used at the vehicle controls treatments for TG2 inhibitors R292 and R294, respectively. *Po0.05 indicates difference from vehicle
control
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further treatment. After incubation, HUVECs were labelled with 2 mM Calcein AM
for 15min and photographed using a fluorescent inverted microscope fitted with a
 10 objective.
HUVEC 3D culture models. Well-established 3D culture models34 were
used in the angiogenesis study with small modifications. In all, 1 105/well of
HUVEC cells in endothelial cell basal medium (ECBM) were re-suspended in 50 ml
collagen I (to reach a final concentration of 2.5 mg/ml) and then added to 96-well
plates. After forming the gels by incubation at 37 1C, ECBM containing 10 ng/ml of
VEGF was added to the wells with or without TG2 inhibitor R294 at a
concentration of 100mM, while DMSO was used as the vehicle control treatment.
Fresh medium was replaced every day during the 7-day culture period. The
images were taken using a bright-field microscope fitted with a  10 objective.
Toxicity assay. The cytotoxic effect of the in-house inhibitors was evaluated
using the Cell Proliferation Kit II (XTT) (Roche, West Sussex, UK) as described
previously.35
In situ ECM TG2 activity assay. The HUVEC co-culture was cultured for 9
days, media was removed and cells incubated in serum-free EGM medium
containing various concentrations of the antibodies D11D12, TG100 (Thermo,
Loughborough, UK), Cub7402 (Thermo) or the corresponding isotype-matched
control for 1 h at 37 1C. Subsequently, 100mM biotin-cadaverine and 1mM DTT
was added to cells for an additional 2 h at 37 1C. A 10mM EDTA containing
treatment was used as the negative control. The reaction was stopped by adding
2mM EDTA in PBS, pH 7.4 and the cells lifted from the ECM using 0.1% (w/v)
deoxycholate in PBS (pH 7.4) containing 2mM EDTA. The incorporated biotin-
cadaverine was revealed using streptavidin-HRP at 37 1C for 1 h and the signal
detected using OPD substrate.
Aorta ring assay. Four- to six–week-old female Swiss rats were euthanised
by carbon dioxide and the aorta was removed. Aortas were cleaned and divided in
two pieces and placed onto 100 ml of gelled Matrigel in 24-well plates then covered
with another 100ml of Matrigel. Plates were incubated at 37 1C for 20min before
addition of culture medium, EGM-2 containing 50 mM or 100mM of the TG2
inhibitor R294, or vehicle control (0.01% DMSO) or PBS. Aortas were cultured for
8 days and every 48 h media was replaced with fresh medium containing the
different treatments. At the end of this period, pictures of the vascular areas
around the aorta were taken in a random manner using a bright-field microscope
fitted with  10 (matrigel) or  20 (collagen) objective. Maximum outgrowth and
vascular density was analysed in five random fields and the pixel area measured in
every field using ImageJ software. All data were normalised using the control group.
For 3D work, the method of Zhu et al.36 was followed 4–6-week-old female Swiss
rats were euthanised by carbon dioxide and the aorta was removed. Aortas were
cleaned and divided into pieces and placed into 24-well plates 25ml of rat tail
collagen I solution was placed onto the aorta ring so it formed aB8-mm thin disc.
After forming gels at 37 1C for 5min, 300ml of serum-free ECBM containing 10 ng/ml
VEGF (with 0.01% DMSO or 100mMR294) was added to each culture and replaced
with fresh medium during the culture period. At the end of this period, pictures of the
vascular areas around the aorta were taken using a bright-field microscope in a
random manner using a  10 objective.
To stain the endothelial cells in the 3D culture, the collagen gels were fixed with
10% neutral buffered formalin for 20min and gently detached from the dishes with a
transfer pipette. After washing three times with dH2O, the collagen gels were stored
in the last wash for 16 h. The gels were then transferred into 35mm petri dishes with
a bent spatula. The whole-staining process was performed on a rotating platform to
ensure the uniform exchange of reagents. The fixed gels were blocked with 5%
rabbit serum in PBS, pH 7.4 (blocking buffer) for 1 h and then washed once with
PBS, pH 7.4 (5min). After incubating with the primary anti-CD31 antibody in
blocking buffer (1 : 100 dilution) for 1 h at room temperature, the gels were washed
three times with PBS, pH 7.4 (10min/wash). FITC-conjugated rabbit anti-mouse
secondary antibody in blocking buffer (1 : 100 dilution) was incubated with the
collagen gels for 1 h at room temperature, followed by another set of washes with
PBS, pH 7.4 (three times, 10min/wash). The fluorescence signal from the mounted
samples was visualised under a fluorescence microscope with a  20 objective.
Migration and proliferation assays via IncuCyte system. The
experiment was performed using the ESSEN IncuCyte system. Graduated 96-well
plates from ESSEN were pre-coated with FN and used to seed HUVECs.
When reaching 90–95% confluency, a wound was made on every well using the
Wound Maker 96 instrument (ESSEN instruments). For inhibition experiments,
HUVECs were pre-treated for 3 h before wounding and then allowed to migrate
into the wound area at 37 1C for 18 h after the wound was introduced. Cell
migration was monitored and analysed by the IncuCyte software.
After incubation for 96 h at 37 1C, the proliferation of HUVEC-TG2wt or HUVEC-
TG2kd cells (5 103 cells/well in complete EGM medium) was studied by
measuring the fluorescence in two different fields per well was measured every 3 h.
The mean of the data was calculated and plotted in using the ESSEN IncuCyte
software.
Western blot and fluorescence staining. SDS–PAGE and western
blotting was performed by using specific antibodies listed in Supplementary Table S4
as described previously, while the membranes were re-probed with a-tubulin as
the loading control. For the ECM VEGF, the matrix fraction was collected from
HUVECs cultured in either 60mm petri dishes (1 106 cells/dish) for 48 h with
treatments. Following lifting the cells with 2mM EDTA in PBS, pH 7.4, the
remaining matrix was incubated with 0.1% deoxycholate in 2 mM EDTA in PBS,
pH 7.4 for 10min. After washing twice with PBS, pH 7.4, the remaining matrices
were collected and denatured in Laemmli buffer for western blotting.
For actin cytoskeleton and FA staining, cells were fixed in 3.7% formaldehyde in
PBS, pH 7.4, permeabilised with 0.1% Triton X-100 in PBS, pH 7.4 and blocked with
3% BSA in PBS, pH 7.4 (blocking buffer) at 37 1C for 30min. Cells were then
incubated 1 h at 37 1C with FITC or TRITC-conjugated phalloidin for F-actin in
blocking buffer. Anti-vinculin antibody and TRITC-conjugated secondary antibody
were used for detecting the FAs.
To detect FN deposited by HUVECs, cells (7 104/chamber in complete EGM
medium) were cultured for 48 h in chamber slides. Live cells were cultured with anti-
FN antibody for 2 h and then fixed, permeabilised and incubated with TRITC-
conjugated secondary antibody for 2 h at 37 1C, as described above. Cells were
finally mounted with Vectashield mounting medium (Vector Laboratories,
Peterborough, UK) and the fluorescence signals visualised using a Leica
epifluorescent microscope (Milton Keynes, UK). For the biotin-labelled FN
deposition, the cells were cultured with biotin-labelled FN (50 nM) for 48 h and
the presence of the labelled FN in the remaining ECM was detected using Cy5-
conjugated Strep-Avidin and Extr-Avidin via confocal microscopy and western
blotting, respectively, as described previously.8
Co-immunoprecipitation. The co-immunoprecipitation was performed as
introduced previously (Wang et al.8). Briefly, HUVECs were treated with TG2
inhibitor R294 (100mM) or 0.01% DMSO (the vehicle control) for 48 h and lysed in
the co-immunoprecipitation buffer (0.25% sodium deoxycholate, 150mM NaCl,
0.1 mM phenylmethylsulfonyl fluoride, 1% (v/v) protein inhibitor mixture). Following
pre-clearing the cell lysates, 200mg of cell lysates were incubated with 0.5mg of
anti-b1 integrin antibody for 90min and subsequently incubated with 50 ml of
Protein A beads for 2 h. The b1 integrin complex was extracted from the beads via
boiling the sample with Laemmli buffer for 5min and the presence of VEGFR2 was
detected via western blotting as described above.
The CAM assay. One day fertilised eggs were incubated for 4 days at 37.5 1C
and 60–70% humidity. At day 4,B2ml of albumin was removed from the egg and
a small window made on the upper part of the egg. Two disks of 0.5 mm pre-
soaked in R294 (100mM) or the vehicle 0.01% DMSO were then introduced
around the embryo on the vascular area. After 6 days, pictures were taken of the
disk areas and the number of vascular branches were counted both in the disk
area and in the invading branches to the disk area as described previously.37 All
data were normalised to their own control in the same egg, and expressed as
arbitrary units. Statistical analysis was then undertaken by the Kruskal–Wallis test.
Angiogenesis induction in mice using Matrigel plug assay.
Balb/C female mice of 4–6 weeks old (Harlan Laboratories Inc, Horst, the
Netherlands) were housed at 22 1C, with water and food freely available and with
a 12 h light/dark cycle. The animals were cared for and used in accordance with
the regulations in Finland (62/2006 and 36/EEo/2006) and the European Union
(86/609/EC). In addition, the protocol was approved by the Finnish authorities and
the Turku Central Animal Laboratory, Turku University, Finland.
Matrigel containing 10mg/kg of EPO to induce angiogenesis as well as inhibitors
for TG2 (at 250 or 500 mM) or their respective vehicle control (PBS or DMSO) were
injected subcutaneously in the right flank of Balb/C mice. Mice were then injected on
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a daily basis with 500ml of inhibitor (250 and 500mM) or vehicle at the site of the
Matrigel plug. After 8 days, the skin containing the Matrigel plugs was excised and
snap-frozen. Frozen sections were fixed in 4% paraformaldehyde and analysed by
immunofluorescence first using an anti-von Willebrant factor antibody and a
secondary antibody labelled with Alexa 488. Sections were counter stained with
4, 6-diamidino-2-phenylindole. Samples were visualised using an Olympus BX60
epifluorescent microscope (Southend-on-Sea, UK) quantitative data were obtained
by counting the number of von Willebrant-positive blood vessels and the total
number of positively staining cells in five randomly chosen separate areas in
digitalised images covering the whole Matrigel area, using ImageJ software. Data
shown are normalised to the control group and expressed in arbitrary units.
Statistical analysis. Unless stated otherwise, all values are presented as the
mean±S.D. Data analyses were performed using either the Turkey and Dunnet
test or the Student’s t-test. A P-value of less than 0.05 was considered to indicate
statistical significance, which is indicated in the text. For in vivo angiogenesis
assays in mice, the statistical analysis used was the Kruskal–Wallis test.
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